{"id":826864,"date":"2025-03-18T08:34:58","date_gmt":"2025-03-18T12:34:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-participate-at-the-11th-annual-immuno-oncology-360-conference-2025\/"},"modified":"2025-03-18T08:34:58","modified_gmt":"2025-03-18T12:34:58","slug":"in8bio-to-participate-at-the-11th-annual-immuno-oncology-360-conference-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-participate-at-the-11th-annual-immuno-oncology-360-conference-2025\/","title":{"rendered":"IN8bio to Participate at the 11th Annual Immuno-Oncology 360\u00b0 Conference 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">NEW YORK, March  18, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-hiXYZrHJN79RIPQiHnBqmeFptcmheg5Eo1gcs3MKbTSMOLlammsIUsKh8vGQIFWE_4ACS9oD-fl2FFtzaFFvQ==\" rel=\"nofollow\" target=\"_blank\"><strong>IN8bio, Inc<\/strong><\/a><strong>. (Nasdaq: INAB)<\/strong>, a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that the Company will participate in multiple sessions at the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7tbq7pki4dSC2QPmYmiOEe1m8sznNhvKxqMSzDxxDBMGpY5ZLZTkoNd2eMnTRaqN0waMpSOTtNBzjP4NUNciE-bxK6z62TLimetSK2TWqI0=\" rel=\"nofollow\" target=\"_blank\">Immuno-Oncology 360\u00b0<\/a> (IO360\u00b0) Conference 2025, held March 24-26, 2025, in Boston, MA.<\/p>\n<p>William Ho, Chief Executive Officer and co-founder of IN8bio, will be Co-Chairing Day 2 of the conference starting at 8:15 AM EDT on March 25, 2025. He will deliver the welcoming remarks and discuss, \u201c<em>Tackling the Tough Questions in IO for Autoimmunity Disease.<\/em>\u201d After, he will Chair the session, \u201c<em>State of the IO Market, Investments and Deals Plenary<\/em>.\u201d<\/p>\n<p>During the afternoon session, at 4:35 PM EDT, Mr. Ho will present on the topic of \u201c<em>Picking our Horse in the Race for Autoimmunity: The Gamma-Delta T cell Engager<\/em>,\u201d and provide a corporate overview of IN8bio\u2019s recently announced INB-619, T cell engager program for oncology and autoimmune diseases.<\/p>\n<p>As co-chair and panelist, Mr. Ho expects to discuss the rationale and promise of a gamma-delta T cell engager in addressing autoimmunity, a rapidly emerging frontier for immunotherapies.<\/p>\n<p>\n        <strong>Presentation and Panel Details<\/strong>\n      <\/p>\n<p>Co-Chairs&#8217; Welcome &amp; Tackling the Tough Questions in IO for Autoimmunity Disease<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:5pt;margin-bottom:5pt\">Date\/Time: March 25, 2025, at 8:15 AM EDT<\/li>\n<\/ul>\n<p>Picking Our Horse in the Race for Autoimmunity: The Gamma-Delta T Cell Engager<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:5pt;margin-bottom:5pt\">Date\/Time: March 25, 2025, at 4:35 PM EDT<\/li>\n<\/ul>\n<p>For those interested in coordinating a time to meet with the IN8bio during IO360\u00b0, please email <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jtnMdTnnnGBELW1agRruvwfBxzAgHP-JVbVo8ZmMr9MQzlZM0M-I6z_Yf0AK2OXkKBWOyDf4nGRCimwasbqqHg==\" rel=\"nofollow\" target=\"_blank\">glenn@z3bio.com<\/a>.<\/p>\n<p>For more information about the event, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8Yz5a-q9mJ3jtPDNOCmI6GESU2LBI32KADnA56kiNnV19cZZ4skruuOaW--UTMPIM0x5q8OglvynRqhw62XRZ8YaLnK7B5uDlj0RTkpPxMI=\" rel=\"nofollow\" target=\"_blank\">https:\/\/io360summit.com<\/a>.<\/p>\n<p>\n        <strong>About IN8bio<\/strong><br \/>\n        <br \/>IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company&#8217;s lead program, INB-100, is focused on acute myeloid leukemia evaluating haplo-matched allogeneic gamma-delta T cells given to patients following a hematopoietic stem cell transplant. The company is also evaluating autologous DeltEx DRI gamma-delta T cells, in combination with standard of care, for glioblastoma, and advancing novel gamma-delta T cell engagers for potential oncology and autoimmune indications. For more information about IN8bio, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YuhJ4fOLNxlQEemrMQB3aQQ-3hspMASuXlxRGSgOiCGjaV5dpC-4C-aYmhVF3rSyvCMYQFRGW2h4SwO4EJXk-fKIQ24i50hChvPqxRhcviQN_TyEw1uW9n-cz13NCtWmJ-mDHuNbSzTofrsZLkgrLGApVKYcUiqoSdgLF5jn6We6Cr6Zywc0B5ljdMzr91YehA_Te4ma-0Fx6iqU0iwzFcN_2Qx0U-fQYYv3CVnec18=\" rel=\"nofollow\" target=\"_blank\">www.IN8bio.com<\/a>.<\/p>\n<p>\n        <strong>Investors &amp; Company Contacts:<\/strong><br \/>\n        <br \/>Glenn Schulman, PharmD, MPH<br \/>203.494.7411<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jtnMdTnnnGBELW1agRruv1VRQz3NVlbgeGl54RSlZsWUgnEUm7unnTQjkpHi3-xHmmt5CVS81AaOjYmOATHyz0C7gDZQ9Y39cv1zvqZJEtM=\" rel=\"nofollow\" target=\"_blank\">glenn@z3bio.com<\/a><\/p>\n<p>IN8bio, Inc.<br \/>Patrick McCall<br \/>646.933.5603<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xi0EOuj_aJ0C1tob3KwUWH3xT3ye0lry2DZIDUY5-8J12BeE6oTzKKZuZCFWFiJA0ANpV2ny-nBorzpkoYLPphDpQzI0dL_JEfjIZHJRIiI=\" rel=\"nofollow\" target=\"_blank\">pfmccall@IN8bio.com<\/a><\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Kimberly Ha<br \/>KKH Advisors<br \/>917.291.5744<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ThsWiZzT4X9Vdjvu0eA9tAVu_I2zW1JFEv-UJPqjfy_cpkdzTcckegQUgF6S6JQX3_wO2jQrvIrV1jg-1n3LgEl7hsfWVyt-LiRO3oC6Imrga5lQDIQFyEAx86VD1U_TVVrCQiUUCMaqwx3Ocb6NXP6Nx0c0G0lAWxrBGpWV4NY3qtyHeaaaZVzZRgBDlvKEVUry_iEnrnWQLZdcnf0_8Nn9_mQFJCP4piVEsoPfMgCx5JOVAjaIl80ZJT-_UeLOeaHNWPxFUwuFUaVmly72fBOMR61ARcIGrg5LhW1pZz2EczvjeQ8MQUyB-97iJOpK\" rel=\"nofollow\" target=\"_blank\">kimberly.ha@kkhadvisors.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTk1NCM2ODEwNTg0IzIxMjMwMDY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZGI3YzE4ZTgtNTZiYi00YTE2LWI3ODgtYzY3Yzk1MDgxMTRlLTExMzQ1NzctMjAyNS0wMy0xOC1lbg==\/tiny\/IN8bio-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) &#8212; IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that the Company will participate in multiple sessions at the Immuno-Oncology 360\u00b0 (IO360\u00b0) Conference 2025, held March 24-26, 2025, in Boston, MA. William Ho, Chief Executive Officer and co-founder of IN8bio, will be Co-Chairing Day 2 of the conference starting at 8:15 AM EDT on March 25, 2025. He will deliver the welcoming remarks and discuss, \u201cTackling the Tough Questions in IO for Autoimmunity Disease.\u201d After, he will Chair the session, \u201cState of the IO Market, Investments and Deals Plenary.\u201d During the afternoon session, at 4:35 PM EDT, Mr. Ho will &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-participate-at-the-11th-annual-immuno-oncology-360-conference-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;IN8bio to Participate at the 11th Annual Immuno-Oncology 360\u00b0 Conference 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-826864","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IN8bio to Participate at the 11th Annual Immuno-Oncology 360\u00b0 Conference 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-participate-at-the-11th-annual-immuno-oncology-360-conference-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IN8bio to Participate at the 11th Annual Immuno-Oncology 360\u00b0 Conference 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) &#8212; IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that the Company will participate in multiple sessions at the Immuno-Oncology 360\u00b0 (IO360\u00b0) Conference 2025, held March 24-26, 2025, in Boston, MA. William Ho, Chief Executive Officer and co-founder of IN8bio, will be Co-Chairing Day 2 of the conference starting at 8:15 AM EDT on March 25, 2025. He will deliver the welcoming remarks and discuss, \u201cTackling the Tough Questions in IO for Autoimmunity Disease.\u201d After, he will Chair the session, \u201cState of the IO Market, Investments and Deals Plenary.\u201d During the afternoon session, at 4:35 PM EDT, Mr. Ho will &hellip; Continue reading &quot;IN8bio to Participate at the 11th Annual Immuno-Oncology 360\u00b0 Conference 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-participate-at-the-11th-annual-immuno-oncology-360-conference-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-18T12:34:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTk1NCM2ODEwNTg0IzIxMjMwMDY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-participate-at-the-11th-annual-immuno-oncology-360-conference-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-participate-at-the-11th-annual-immuno-oncology-360-conference-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"IN8bio to Participate at the 11th Annual Immuno-Oncology 360\u00b0 Conference 2025\",\"datePublished\":\"2025-03-18T12:34:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-participate-at-the-11th-annual-immuno-oncology-360-conference-2025\\\/\"},\"wordCount\":403,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-participate-at-the-11th-annual-immuno-oncology-360-conference-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTk1NCM2ODEwNTg0IzIxMjMwMDY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-participate-at-the-11th-annual-immuno-oncology-360-conference-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-participate-at-the-11th-annual-immuno-oncology-360-conference-2025\\\/\",\"name\":\"IN8bio to Participate at the 11th Annual Immuno-Oncology 360\u00b0 Conference 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-participate-at-the-11th-annual-immuno-oncology-360-conference-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-participate-at-the-11th-annual-immuno-oncology-360-conference-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTk1NCM2ODEwNTg0IzIxMjMwMDY=\",\"datePublished\":\"2025-03-18T12:34:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-participate-at-the-11th-annual-immuno-oncology-360-conference-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-participate-at-the-11th-annual-immuno-oncology-360-conference-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-participate-at-the-11th-annual-immuno-oncology-360-conference-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTk1NCM2ODEwNTg0IzIxMjMwMDY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NTk1NCM2ODEwNTg0IzIxMjMwMDY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-participate-at-the-11th-annual-immuno-oncology-360-conference-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IN8bio to Participate at the 11th Annual Immuno-Oncology 360\u00b0 Conference 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IN8bio to Participate at the 11th Annual Immuno-Oncology 360\u00b0 Conference 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-participate-at-the-11th-annual-immuno-oncology-360-conference-2025\/","og_locale":"en_US","og_type":"article","og_title":"IN8bio to Participate at the 11th Annual Immuno-Oncology 360\u00b0 Conference 2025 - Market Newsdesk","og_description":"NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) &#8212; IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that the Company will participate in multiple sessions at the Immuno-Oncology 360\u00b0 (IO360\u00b0) Conference 2025, held March 24-26, 2025, in Boston, MA. William Ho, Chief Executive Officer and co-founder of IN8bio, will be Co-Chairing Day 2 of the conference starting at 8:15 AM EDT on March 25, 2025. He will deliver the welcoming remarks and discuss, \u201cTackling the Tough Questions in IO for Autoimmunity Disease.\u201d After, he will Chair the session, \u201cState of the IO Market, Investments and Deals Plenary.\u201d During the afternoon session, at 4:35 PM EDT, Mr. Ho will &hellip; Continue reading \"IN8bio to Participate at the 11th Annual Immuno-Oncology 360\u00b0 Conference 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-participate-at-the-11th-annual-immuno-oncology-360-conference-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-18T12:34:58+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTk1NCM2ODEwNTg0IzIxMjMwMDY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-participate-at-the-11th-annual-immuno-oncology-360-conference-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-participate-at-the-11th-annual-immuno-oncology-360-conference-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"IN8bio to Participate at the 11th Annual Immuno-Oncology 360\u00b0 Conference 2025","datePublished":"2025-03-18T12:34:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-participate-at-the-11th-annual-immuno-oncology-360-conference-2025\/"},"wordCount":403,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-participate-at-the-11th-annual-immuno-oncology-360-conference-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTk1NCM2ODEwNTg0IzIxMjMwMDY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-participate-at-the-11th-annual-immuno-oncology-360-conference-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-participate-at-the-11th-annual-immuno-oncology-360-conference-2025\/","name":"IN8bio to Participate at the 11th Annual Immuno-Oncology 360\u00b0 Conference 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-participate-at-the-11th-annual-immuno-oncology-360-conference-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-participate-at-the-11th-annual-immuno-oncology-360-conference-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTk1NCM2ODEwNTg0IzIxMjMwMDY=","datePublished":"2025-03-18T12:34:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-participate-at-the-11th-annual-immuno-oncology-360-conference-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-participate-at-the-11th-annual-immuno-oncology-360-conference-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-participate-at-the-11th-annual-immuno-oncology-360-conference-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTk1NCM2ODEwNTg0IzIxMjMwMDY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NTk1NCM2ODEwNTg0IzIxMjMwMDY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-participate-at-the-11th-annual-immuno-oncology-360-conference-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"IN8bio to Participate at the 11th Annual Immuno-Oncology 360\u00b0 Conference 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/826864","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=826864"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/826864\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=826864"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=826864"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=826864"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}